Enzymatic synthesis of chiral intermediates for pharmaceuticals.
There has been an increasing awareness of the enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enatioselective manner. Chiral intermediates are in high demand by pharmaceutical industries for the preparation bulk drug substances. In this review article, microbial/enzymatic processes for the synthesis of chiral intermediates for antihypertensive drugs, melatonin receptor agonists, and beta3-receptor receptor agonists are described.
Patel
Ramesh
R
Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey, 08903, USA. Patelr@bms.com
Hanson
Ronald
R
Goswami
Animesh
A
Nanduri
Venkata
V
Banerjee
Amit
A
Donovan
Mary-Jo
MJ
Goldberg
Steven
S
Johnston
Robert
R
Brzozowski
David
D
Tully
Thomas
T
Howell
Jeffrey
J
Cazzulino
Dana
D
Ko
Rapheal
R
D058667:Adrenergic beta-3 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000378:metabolism*; D000959:Antihypertensive Agents / Q000378:metabolism*; D001711:Biotransformation; D002626:Chemistry, Pharmaceutical; D004798:Enzymes / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000819:agonists* / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism*; D044094:Receptors, Melatonin; D013237:Stereoisomerism
D058667:Adrenergic beta-3 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000959:Antihypertensive Agents; D004798:Enzymes; D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin